Efficacy of Brahmi vati in generalised anxiety disorder – Randomized double blind comparative clinical trial

Generalized Anxiety Disorder (GAD) is the most common anxiety disorder. GAD has high comorbidities and it can affect social, professional and personal life. Ayurvedic medicine, Brahmi vati is explored for the possible role in management of GAD and is compared to Manasmitra vataka. To evaluate the ef...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of ayurveda and integrative medicine Vol. 13; no. 2; p. 100552
Main Authors:	Khot, Siddhi G., Tubaki, Basavaraj R., Gonugade, Varsha B.
Format:	Journal Article
Language:	English
Published:	United States Elsevier B.V 01-04-2022 Elsevier
Subjects:	Ayurveda Brahmi vati Generalized Anxiety Disorder Manasmitra vataka Original Sleep Ayurveda Sleep Generalized Anxiety Disorder Brahmi vati Manasmitra vataka
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Generalized Anxiety Disorder (GAD) is the most common anxiety disorder. GAD has high comorbidities and it can affect social, professional and personal life. Ayurvedic medicine, Brahmi vati is explored for the possible role in management of GAD and is compared to Manasmitra vataka. To evaluate the efficacy of B. vati on Generalized Anxiety Disorder. A randomized double blind controlled trial, with total 56 patients meeting the DSM V criteria of GAD between 20–60 years of age and either sex participated in the study. Participants were randomly divided into two groups, Brahmi group received capsule B. vati 500 mg and Manasmitra group received capsule M. vataka 500 mg thrice a day with water for 45 days. Assessments were conducted through various clinical parameters such as Hamilton Anxiety Rating Scale (HARS), GAD 7 scale (GAD 7), Beck Depression Inventory scale (BDI), Epworth sleepiness scale (ESS), Pittsburgh Sleep Quality Index (PSQI), WHO Quality of Life- BREF (WHOQOL-BREF), Clinical Global Improvement scale (CGI). Blood variables including Haemoglobin, Erythrocyte Sedimentation Rate (ESR), Liver Function Test (LFT) and serum creatinine were assessed before and after the study. Assessments during intervention were conducted on every 15th day. Study results indicate that both B. vati and M. vataka were comparable and each produced significant improvement (p < 0.001) in HARS, GAD-7, BDI, ESS, PSQI, WHOQOL-BREF and CGI. Brahmi vati also produced significant decrease in systolic (p = 0.002) and diastolic (p < 0.001) blood pressure. Both groups showed good safety profile evaluated through the assessment of serum creatinine levels and LFT. B. vati and M. vataka were effective, safe and comparable in the management of GAD. Warrants further studies.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0975-9476 0976-2809
DOI:	10.1016/j.jaim.2022.100552